Cancer Institute and Hospital, Chinese Academy of Medical Sciences: Carcinoma trials

The registry lists 16 Carcinoma studies with Cancer Institute and Hospital, Chinese Academy of Medical Sciences as lead sponsor. 7 are open to participants now and 1 have results posted.

Phase 1 1Phase 2 12Phase 3 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Hypofractionated Radiotherapy for HNSCC in Elderly PatientsEnrolling by invitationNCT06768125Not applicable
• Application of Integrated Proteomic and Serum Metabolomic Analysis in Assessing the Efficacy and Prognosis of TACE Combined With Targeted Immunotherapy in Unresectable Hepatocellular CarcinomaEnrolling by invitationNCT06540508
• GP Combined With Nimotuzumab and Sintilimab as Induction Therapy for Nasopharyngeal CarcinomaNot yet recruitingNCT06490341Phase 2
• Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor ThrombosisRecruitingNCT06389422Phase 2
• Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCCRecruitingNCT06170710Phase 2
• Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell CarcinomaRecruitingNCT06170697Phase 2
• Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal CarcinomaRecruitingNCT05448885Phase 2
• Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical ResectionCompletedNCT03575806Phase 2Results posted
• Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the CervixActive, not recruitingNCT06771596Phase 2
• Pembrolizumab Plus CRT Followed by Surgery in Upper ESCCStatus unknownNCT05541445Phase 1/2
• SBRT With DIBH for HCC After TACE and Lipiodol MarkingActive, not recruitingNCT05021250Not applicable
• A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and OxaliplatinStatus unknownNCT04850040Phase 2
• Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma with PVTTTerminatedNCT04709380Phase 3
• Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial CarcinomaStatus unknownNCT04099589Phase 2
• Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical ResectionStatus unknownNCT03839550Phase 2
• Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular CarcinomaCompletedNCT03535259Phase 2